Treatment of Retroperitoneal Well‑Differentiated Liposarcoma with Combination of Penpulimab and Anlotinib: A Case Report and Literature Review

Abstract

To observe the efficacy of combination therapy with Penpulimab and Anlotinib in the treatment of retroperitoneal well‑differentiated  liposarcoma. Retrospective analysis of clinical data of a patient with retroperitoneal well‑differentiated soft tissue sarcoma admitted to  Shaoxing People’s Hospital, and review of relevant literature. The patient is a young male who experienced recurrence of retroperitoneal  well‑differentiated liposarcoma after two surgeries. After first‑line treatment with Anlotinib combined with Penpulimab, the patient  achieved almost complete remission with a progression free survival period of about 16 months. The first‑line treatment of  retroperitoneal well‑differentiated soft tissue sarcoma using Anlotinib combined with Penpulimab resulted in a good prognosis.